Advaxis, Inc. (ADXS) Stock: What Does the Chart Say Wednesday?

Wednesday, December 29, 2021 11:08 AM | InvestorsObserver Analysts

Mentioned in this article

Advaxis, Inc. (ADXS) Stock: What Does the Chart Say Wednesday?

Advaxis, Inc. (ADXS) stock has fallen 55.17% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Advaxis, Inc. has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ADXS!

See Full ADXS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ADXS Stock Today?

Advaxis, Inc. (ADXS) stock is down -14.57% while the S&P 500 is up 0.07% as of 10:51 AM on Wednesday, Dec 29. ADXS is lower by -$0.02 from the previous closing price of $0.15 on volume of 2,226,351 shares. Over the past year the S&P 500 has gained 28.23% while ADXS is lower by -63.89%. ADXS lost -$0.20 per share in the over the last 12 months. To screen for more stocks like Advaxis, Inc. click here.

More About Advaxis, Inc.

Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer. Click Here to get the full Stock Report for Advaxis, Inc. stock.